Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.73 |
| ▸ | LPAR1 | Q92633 | 18/20 | 0.70 |
| ▸ | LPAR5 | Q9H1C0 | 18/20 | 0.70 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9762139 | 0.88 | PARP10 (0.71) | PARP10LPAR1LPAR5SRD5A2 | |
| SCHEMBL7706043 | 0.87 | SRD5A2 (0.68) | PARP10LPAR1LPAR5SRD5A2 | |
| SCHEMBL3135333 | 0.86 | LPAR1 (0.56) | PARP10LPAR1LPAR5SRD5A2 | |
| Hydrochloric Acid SCHEMBL8433836 | 0.85 | SRD5A2 (0.66) | PARP10LPAR1LPAR5SRD5A2 | |
| Hydrochloric Acid SCHEMBL8433842 | 0.85 | SRD5A2 (0.66) | PARP10LPAR1LPAR5SRD5A2 | |
| SCHEMBL8628620 | 0.85 | LPAR1 (0.58) | PARP10LPAR1LPAR5SRD5A2 | |
| SCHEMBL9762806 | 0.84 | PARP10 (0.71) | PARP10LPAR1LPAR5 | |
| SCHEMBL3022362 | 0.84 | PARP10 (1.00) | PARP10LPAR1LPAR5 | |
| SCHEMBL30289632 | 0.84 | PARP10 (1.00) | PARP10LPAR1LPAR5 | |
| SCHEMBL16507486 | 0.84 | LPAR1 (1.00) | LPAR1LPAR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115894497-A | Imidazopyrimidine compounds, and preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-109311860-A | For treating or preventing the Xanthone derivative of hepatitis type B virus disease | 豪夫迈·罗氏有限公司 | 2019-02-05 | — | — | CN | disclosed |
| US-20190010129-A1 | Amide derivatives as lysophosphatidic acid receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2019-01-10 | — | — | US | disclosed |
| US-10100018-B2 | Amide derivatives as lysophosphatidic acid receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-16 | — | — | US | disclosed |
| EP-2773352-B1 | 1-SUBSTITUTED 4-ARYLPIPERAZINE AS KAPPA OPIOID RECEPTOR ANTAGONISTS | RES TRIANGLE INST (US) | 2017-06-28 | — | — | EP | disclosed |
| US-9512105-B2 | 1-substituted 4-arylpiperazine as kappa opioid receptor antagonists | RESEARCH TRIANGLE INSTITUTE (US) | 2016-12-06 | — | — | US | disclosed |
| US-9464060-B2 | Compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-10-11 | — | — | US | disclosed |
| US-9464060-B2 | Compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-10-11 | — | — | US | disclosed |
| US-9464060-B2 | Compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-10-11 | — | — | US | disclosed |
| US-20160207880-A1 | AMIDE DERIVATIVES AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-07-21 | — | — | US | disclosed |
| CN-104163772-A | Substituted diaryl ester compound, and preparation method and application thereof | UNIV XIAMEN | 2014-11-26 | — | — | CN | disclosed |
| EP-2773352-A2 | 1-SUBSTITUTED 4-ARYLPIPERAZINE AS KAPPA OPIOID RECEPTOR ANTAGONISTS | Research Triangle Institute, International (US) | 2014-09-10 | — | — | EP | disclosed |
| WO-2013086496-A2 | 1-SUBSTITUTED 4-ARYLPIPERAZINE AS KAPPA OPIOID RECEPTOR ANTAGONISTS | RESEARCH TRIANGLE INSTITUTE (US) | 2013-06-13 | — | — | WO | disclosed |
| EP-1873153-B1 | 3-AZETIDINECARBOXYLIC ACID DERIVATIVES FOR USE AS IMMUNOSUPPRESSANTS | DAIICHI SANKYO CO LTD (JP) | 2010-07-07 | — | — | EP | disclosed |
| US-7687491-B2 | Heterocyclic compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-03-30 | — | — | US | disclosed |
| CN-101203512-A | Heterocyclic compounds | DAIICHI SANKYO CO LTD (JP) | 2008-06-18 | — | — | CN | disclosed |
| US-20080113961-A1 | Immunosuppressants with low toxicity; 1-({4-Methyl-5-[5-(4-phenoxyphenyl)-1,2,4-oxadiazol-3-yl]-2-thienyl}methyl)azetidine-3-carboxylic acid for example; autoimmune diseases and transplant rejection; N-substituted azetidine, pyrrolidine or piperidine compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-05-15 | — | — | US | disclosed |
| EP-1873153-A1 | HETEROCYCLIC COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2008-01-02 | — | — | EP | disclosed |
| US-5012017-A | Peroxide oxidation of halogenated phenoxyphenones to phenoxyophenyl esters, then conversions to phenoxyphenols | DOWELANCO (US) | 1991-04-30 | — | — | US | disclosed |
| WO-1990009979-A1 | METHODS FOR THE PREPARATION OF BROMINATED INTERMEDIATES | THE DOW CHEMICAL COMPANY (US) | 1990-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10100018-B2 | Amide derivatives as lysophosphatidic acid receptor antagonists | LPAR1, LPAR2, LPAR3 | PARP10 1379/4885LPAR1 1/4885LPAR5 5/4885 |
| US-20190010129-A1 | Amide derivatives as lysophosphatidic acid receptor antagonists | LPAR1, LPAR2, LPAR3 | PARP10 1364/4885LPAR1 1/4885LPAR5 5/4885 |
| US-20080113961-A1 | Immunosuppressants with low toxicity; 1-({4-Methyl-5-[5-(4-phenoxyphenyl)-1,2,4-oxadiazol-3-yl]-2-thienyl}methyl)azetidine-3-carboxylic acid for example; autoimmune diseases and transplant rejection; N-substituted azetidine, pyrrolidine or piperidine compounds | TPMT, AZI2, IDO1 | PARP10 4410/4885LPAR1 2850/4885LPAR5 2886/4885 |
| US-20160207880-A1 | AMIDE DERIVATIVES AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR3 | PARP10 1379/4885LPAR1 1/4885LPAR5 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.